JP2022534704A5 - - Google Patents

Info

Publication number
JP2022534704A5
JP2022534704A5 JP2021569903A JP2021569903A JP2022534704A5 JP 2022534704 A5 JP2022534704 A5 JP 2022534704A5 JP 2021569903 A JP2021569903 A JP 2021569903A JP 2021569903 A JP2021569903 A JP 2021569903A JP 2022534704 A5 JP2022534704 A5 JP 2022534704A5
Authority
JP
Japan
Prior art keywords
group
substituted
alkyl
optionally
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021569903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534704A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/035848 external-priority patent/WO2020247445A1/en
Publication of JP2022534704A publication Critical patent/JP2022534704A/ja
Publication of JP2022534704A5 publication Critical patent/JP2022534704A5/ja
Pending legal-status Critical Current

Links

JP2021569903A 2019-06-04 2020-06-03 オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法 Pending JP2022534704A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962856830P 2019-06-04 2019-06-04
US62/856,830 2019-06-04
PCT/US2020/035848 WO2020247445A1 (en) 2019-06-04 2020-06-03 Imidazolo derivatives, compositions and methods as orexin antagonists

Publications (2)

Publication Number Publication Date
JP2022534704A JP2022534704A (ja) 2022-08-03
JP2022534704A5 true JP2022534704A5 (cg-RX-API-DMAC7.html) 2023-06-08

Family

ID=73652477

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021569903A Pending JP2022534704A (ja) 2019-06-04 2020-06-03 オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法

Country Status (9)

Country Link
US (2) US12187737B2 (cg-RX-API-DMAC7.html)
EP (1) EP3972588A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022534704A (cg-RX-API-DMAC7.html)
KR (1) KR20220016918A (cg-RX-API-DMAC7.html)
CN (1) CN114286675A (cg-RX-API-DMAC7.html)
AU (1) AU2020286381C1 (cg-RX-API-DMAC7.html)
CA (1) CA3140170A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112827QA (cg-RX-API-DMAC7.html)
WO (1) WO2020247445A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202112828SA (en) * 2019-06-04 2021-12-30 Hager Biosciences Llc Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
JP2022534704A (ja) 2019-06-04 2022-08-03 ヘイガー バイオサイエンシズ,エルエルシー オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法
KR20220119653A (ko) 2019-12-20 2022-08-30 테나야 테라퓨틱스, 인코포레이티드 플루오로알킬-옥사디아졸 및 이의 용도
US20240252502A1 (en) 2021-05-04 2024-08-01 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of metabolic disease and hfpef
GB202311281D0 (en) 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists
GB202311280D0 (en) 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists
CN122514526A (zh) * 2023-11-08 2026-08-04 汉阳大学校Erica产学协力团 一种6-芳基咪唑并[2,1-b]噻唑/噁唑-2-羧酸衍生物及含有其作为有效成分的用于治疗阿尔茨海默病的药物组合物
WO2025188753A1 (en) * 2024-03-05 2025-09-12 Hager Biosciences, Llc Pyrazole and imidazole derivatives as dual orexin and kappa-opioid receptors modulators, compositions, and methods for treating neurological and psychiatric disorders

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02237988A (ja) 1988-11-18 1990-09-20 Nissan Chem Ind Ltd イソオキサゾロピリジン系メバロノラクトン類
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
JP3810097B2 (ja) 1993-01-15 2006-08-16 明治製菓株式会社 ピロリジン−2−イルカルボニル複素環式化合物誘導体
CA2331735A1 (en) 1998-05-08 1999-11-18 Smithkline Beecham P.L.C. Phenylurea and phenylthio urea derivatives
SK7582001A3 (en) 1998-12-18 2002-03-05 Schering Corp Compound, method of therapy and pharmaceutical composition comprising the same, and its use for farnesyl protein transferase inhibition
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
EP1289955B1 (en) 2000-06-16 2005-04-13 Smithkline Beecham Plc Piperidines for use as orexin receptor antagonists
EP1353918B1 (en) 2000-11-28 2005-01-12 Smithkline Beecham Plc Morpholine derivatives as antagonists of orexin receptors
BR0209334A (pt) 2001-05-05 2004-06-15 Smithkline Beecham Plc Aminas n-aroil cìclicas
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
US7057042B2 (en) 2002-05-29 2006-06-06 Abbott Laboratories Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction
WO2004026866A1 (en) * 2002-09-18 2004-04-01 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
US20080119515A1 (en) 2003-03-10 2008-05-22 M Arshad Siddiqui Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis
SI1836211T1 (sl) 2004-12-21 2010-04-30 Pfizer Prod Inc Makrolidi
DE102005016547A1 (de) 2005-04-08 2006-10-12 Grünenthal GmbH Substituierte 5,6,7,8-Tetrahydro-imidazo(1,2-a)pyridin-2-ylamin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
US20090118200A1 (en) 2005-05-23 2009-05-07 Bergman Jeffrey M Proline bis-amide orexin receptor antagonists
UA100974C2 (ru) * 2006-12-01 2013-02-25 Мерк Шарп Энд Доме Корп. Соединения замещенных диазепанов как антагонисты орексиновых рецепторов
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
HRP20120240T1 (hr) 2007-05-23 2012-04-30 Merck Sharp & Dohme Corp. Piridil piperidin antagonisti receptora za oreksin
US8106215B2 (en) 2007-07-03 2012-01-31 Actelion Pharmaceuticals Ltd. 3-aza-bicyclo[3.3.0]octane compounds
ES2560095T3 (es) 2007-08-10 2016-02-17 Cortex Pharmaceuticals, Inc. Amidas bicíclicas para mejorar las respuestas sinápticas glutamatérgicas
FR2925907B1 (fr) 2008-01-02 2010-10-15 Sanofi Aventis DERIVES DE 2-HETEROAROYL-IMIDAZO°1,2-a!PYRIDINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
CN101918361B (zh) 2008-02-12 2014-05-28 弗·哈夫曼-拉罗切有限公司 哌啶磺酰胺衍生物
AU2009307920A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
AU2009307915A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
JP2012506374A (ja) 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション 2,5−二置換ピペリジンオレキシン受容体アンタゴニスト
WO2010141275A1 (en) 2009-06-01 2010-12-09 Merck Sharp & Dohme Corp. Pyrazine carboxamide orexin receptor antagonists
WO2011005636A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Tetrahydronapthyridine orexin receptor antagonists
MX2012009377A (es) 2010-02-11 2012-09-12 Univ Vanderbilt Benzotiazoles y azabenzotiazoles como potenciadores alostericos mglur4, composiciones y metodos para tratar la disfuncion neurologica.
EP2630138B1 (en) * 2010-10-21 2015-06-03 Bayer Intellectual Property GmbH 1-(heterocyclic carbonyl)-2-substituted pyrrolidines and their use as fungicides
US20120165339A1 (en) 2010-12-22 2012-06-28 Eisai R&D Management Co., Ltd. Cyclopropane derivatives
ES2541531T3 (es) * 2011-02-18 2015-07-21 Actelion Pharmaceuticals Ltd. Nuevos derivados de pirazol e imidazol útiles como antagonistas de orexina
EP2730573A4 (en) 2011-07-05 2014-12-03 Taisho Pharmaceutical Co Ltd METHYLPIPERIDINDERIVAT
US9242995B2 (en) 2011-10-25 2016-01-26 Merck Sharp & Dohme Corp. Isoxazolopyridine orexin receptor antagonists
JP6346862B2 (ja) 2012-02-07 2018-06-20 エオラス セラピューティクス, インコーポレイテッド オレキシンレセプターアンタゴニストとしての置換プロリン/ピペリジン
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
EP4032889B1 (en) 2013-12-20 2026-05-06 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3187497A4 (en) 2014-08-26 2018-02-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP2022534704A (ja) 2019-06-04 2022-08-03 ヘイガー バイオサイエンシズ,エルエルシー オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法
SG11202112828SA (en) * 2019-06-04 2021-12-30 Hager Biosciences Llc Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists

Similar Documents

Publication Publication Date Title
JP2022534709A5 (cg-RX-API-DMAC7.html)
NZ788543A (en) Dimethyltryptamine derivatives and their use in psychedelic-assisted psychotherapy
JP2022545633A5 (cg-RX-API-DMAC7.html)
WO2021193897A1 (ja) 置換ピリダジン化合物
JPH05507071A (ja) 新規化合物
WO2017106226A1 (en) Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
JP2023533203A5 (cg-RX-API-DMAC7.html)
US20220251089A1 (en) Cyclic iminopyrimidine derivatives as kinase inhibitors
JP2022510925A5 (cg-RX-API-DMAC7.html)
JP2021520415A5 (cg-RX-API-DMAC7.html)
JP2013542267A5 (cg-RX-API-DMAC7.html)
JP2023518044A5 (cg-RX-API-DMAC7.html)
TW202214631A (zh) 作為Akt激酶抑制劑的化合物
JP3521214B2 (ja) 4,5−ジヒドロイソオキサゾリルアルキルピペラジン誘導体とその製造方法並びにドーパミン拮抗剤
JP2025502712A5 (cg-RX-API-DMAC7.html)
JP2020516616A5 (cg-RX-API-DMAC7.html)
JP2023507569A5 (cg-RX-API-DMAC7.html)
JP2024526191A5 (cg-RX-API-DMAC7.html)
WO2015180342A1 (zh) 氘取代1-[2-(2,4-二甲基-苯硫基)-苯基]哌嗪化合物或其衍生物及其药物组合物和用途
JP6542236B2 (ja) 有機化合物
WO2014127722A1 (zh) 氮杂环取代二氢青蒿素衍生物及其应用
WO2013147216A1 (ja) (2-ヘテロアリールアミノ)コハク酸誘導体
JP2024515544A5 (cg-RX-API-DMAC7.html)
JP2017516824A5 (cg-RX-API-DMAC7.html)
JP6634157B2 (ja) ジアミノピリジン誘導体